NCT01606995 - Xarelto for Prevention of Stroke in Patients With Atrial Fibrillation | Biotech Hunter

Enrollment

6,784

Participants

Timeline

Start Date

June 12, 2012

Primary Completion Date

March 6, 2015

Study Completion Date

March 31, 2015

Conditions

Atrial Fibrillation

Interventions

DRUG

Rivaroxaban (Xarelto, BAY59-7939)

Patients with non-valvular atrial fibrillation who are prescribed rivaroxaban under routine treatment conditions to prevent stroke or non-central nervous system systemic embolism. Decision regarding dose and duration of treatment made at the discretion of the attending investigator

Trial Locations (21)

Unknown

Multiple Locations